Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Purpose
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.
Conditions
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Participants must have been assigned to S1800E by the Southwest Oncology Group
(SWOG) Statistics and Data Management Center (SDMC). Assignment to S1800E is
determined by the LUNGMAP protocol
- Participants must have measurable or non-measurable disease documented by CT or MRI.
The CT from a combined positron emission tomography (PET)/CT may be used to document
only non-measurable disease unless it is of diagnostic quality. Measurable disease
must be assessed within 28 days prior to randomization. Pleural effusions, ascites
and laboratory parameters are not acceptable as the only evidence of disease.
Non-measurable disease must be assessed within 42 days prior to randomization. All
disease must be assessed and documented on the Baseline Tumor Assessment Form.
Participants whose only measurable disease is within a previous radiation therapy
port must demonstrate clearly progressive disease (in the opinion of the treating
investigator) prior to registration
- Participants must have a CT or MRI scan of the brain to evaluate for central nervous
system (CNS) disease within 42 days prior to randomization
- Participants must have received exactly one anti-PD-1 or anti-PD-L1 therapy for
advanced disease (stage IV or recurrent disease, or stage I-III disease in certain
circumstances outlined below). Anti-PD-1 or anti-PD-L1 therapy may have been given
alone or in combination with other therapy. For participants who received
neoadjuvant, adjuvant, and/or consolidation anti-PD-1 or anti-PD-L1 therapy for
stage I-III disease:
- If they experienced disease progression within (≤) 365 days from initiation
(cycle 1 day 1) or anti-PD-1 or anti-PD-L1 therapy, this counts as the single
allowed anti-PD-1 or anti-PD-L1 therapy for advanced disease
- If they experienced disease progression more than (>) 365 days from initiation
(cycle 1 day 1) or anti-PD-1 or anti-PD-L1 therapy, this is not considered
anti-PD-1 or anti-PD-L1 therapy for advance disease. These participants must
have received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent disease
- Participants must have experienced disease progression (in the opinion of the
treating investigator) more than (>) 84 days following initiation (cycle 1 day 1) of
their most recent anti-PD-1 or anti-PD-L1 therapy
- Participants who received anti-PD-1 or anti-PD-L1 therapy for stage IV or recurrent
disease must have had a best response of stable disease, partial response or
complete response (in the opinion of the treating investigator) on the anti-PD-1 or
anti-PD-L1 therapy for stage IV or recurrent disease
- Participants must have received platinum-based chemotherapy and experienced disease
progression (in the opinion of the treating investigator) during or after this
regimen
- Participants with a known sensitizing molecular alteration for which a Food and Drug
Administration (FDA)-approved targeted therapy for NSCLC exists (e.g., EGFR, ALK,
ROS1, BRAF, RET, NTRK, KRAS, HER2, and MET sensitizing mutations), must have
previously received at least one of the approved therapy(s). Prior targeted therapy
for participants with targetable alterations is allowed if all other eligibility
criteria are also met
- Participants must have recovered (≤ grade 1) from any side effects from the most
recent anti-cancer treatment prior to randomization
- Participants must not have received prior therapy with docetaxel for this disease
- Participants must not have received any palliative radiation therapy within 14 days
(or palliative bone radiation therapy within 7 days) prior to randomization
- Participants must not be planning to receive any concurrent chemotherapy,
immunotherapy, or biologic therapy for cancer treatment while receiving treatment on
this study
- Participants must not have undergone major surgery within 28 days prior to
randomization, or subcutaneous venous access device placement within 7 days prior to
randomization. Participants must not have postoperative bleeding complications or
wound complications from a surgical procedure performed within 2 months prior to
randomization. The participant must not have elective or planned major surgery to be
performed during the course of this study
- Absolute neutrophil count ≥ 1.5 x 10^3/uL (within 28 days prior to randomization)
- Hemoglobin ≥ 9.0 g/dL (within 28 days prior to randomization)
- Platelets ≥ 100 x 10^3/uL (within 28 days prior to randomization)
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days
prior to randomization) unless history of Gilbert's disease. Participants with
history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x
institutional ULN (within 28 days prior to randomization). Participants with history
of liver metastasis must have AST and ALT ≤ 5 x ULN
- Participants must have a creatinine ≤ the institutional (I)ULN or calculated
creatinine clearance ≥ 50 mL/min using the following Cockcroft-Gault formula. This
specimen must have been drawn and processed within 28 days prior to randomization
- Participants must have a urinary protein test performed within 28 days prior to
randomization
- Participants' most recent Zubrod/Eastern Cooperative Oncology Group (ECOG)
performance status must be 0-1 and be documented within 28 days prior to
randomization
- Participants must have a completed medical history and physical exam within 28 days
prior to randomization
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load while on suppressive therapy on the most recent test
results obtained within 6 months prior to randomization, if indicated by the
treating investigator
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants currently being treated for HCV infection must have
undetectable HCV viral load test on the most recent test results obtained within 6
months prior to randomization, if indicated by the treating investigator
- Participants with known human immunodeficiency virus (HIV) infection are eligible,
provided they are on effective anti-retroviral therapy and have undetectable viral
load at their most recent viral load test and within 6 months prior to randomization
- Participants must not have a prior or concurrent malignancy whose natural history or
treatment has the potential to interfere with the safety or efficacy assessment of
the investigational regimen
- Participants must not have an active autoimmune disease that has required systemic
treatment within 730 days prior to randomization (i.e., with use of disease
modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy
(e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for
adrenal or pituitary insufficiency) is not considered a form of systemic treatment
and is allowed
- Participants must not have any history of primary immunodeficiency
- Participants must be able to safely receive study therapy and must not have
experienced the following:
- Any grade 3 or worse immune-mediated adverse event. Exception: asymptomatic
nonbullous/nonexfoliative rash
- Any unresolved grade 2 immune-mediated adverse event
- Any toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1
immunotherapy
- Exception to the above: Toxicities of any grade that requires replacement
therapy and has stabilized on therapy (e.g., thyroxine, insulin, or physiologic
corticosteroid replacement therapy for adrenal or pituitary insufficiency) are
allowed
- Participants must not have any history of organ transplant that requires use of
immunosuppressives
- Participants must not have received a live or live attenuated vaccine within 28 days
prior to randomization. Examples of live vaccines include, but are not limited to,
the following: measles, mumps, rubella, varicella/zoster, yellow fever rabies,
Bacillus Calmette-Guerin (BCG) and typhoid vaccine. Seasonal influenza vaccines and
COVID-19 vaccines are allowed, however, intranasal influenza vaccines (e.g.
Flu-Mist) are live attenuated and are not allowed
- Participants must not have clinical signs or symptoms of active tuberculosis
infection
- Participants must not have a history of (non-infectious) pneumonitis that required
steroids or current pneumonitis/interstitial lung disease
- Participants must not have had a serious or nonhealing wound, ulcer, or bone
fracture within 28 days prior to randomization
- Participants must not have a history of gastrointestinal perforation or fistula
within 6 months prior to randomization
- Participants must not have grade 3-4 gastrointestinal bleeding (defined by National
Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]
version [v]5) within 3 months prior to randomization. No history of gastrointestinal
(GI) bleed within 3 months prior to randomization
- Participants must not have any grade III/IV cardiac disease as defined by the New
York Heart Association criteria (i.e., participants with cardiac disease resulting
in marked limitation of physical activity or resulting in inability to carry on any
physical activity without discomfort), unstable angina pectoris, and myocardial
infarction within 6 months prior to randomization, or serious uncontrolled cardiac
arrhythmia
- Participants must not have experienced any arterial thromboembolic events, including
but not limited to myocardial infarction, transient ischemic attack, cerebrovascular
accident, or unstable angina, within 6 months prior to randomization
- Participants must not have gross hemoptysis within two months prior to randomization
(defined as bright red blood or ≥ 1/2 teaspoon) or with radiographic evidence of
intratumor cavitation or has radiologically documented evidence of major blood
vessel invasion or encasement by cancer
- Participants must not have been diagnosed with venous thrombosis within 3 months
prior to randomization. Participants with venous thrombosis diagnosed more than 3
months prior to randomization must be on stable doses of anticoagulants
- Participants must not have cirrhosis at a level of Child-Pugh B (or worse) AND a
history of hepatic encephalopathy or clinically meaningful ascites resulting from
cirrhosis, OR any degree of cirrhosis
- Participants must not be pregnant or breastfeeding (nursing includes breast milk fed
to an infant by any means, including from the breast, milk expressed by hand, or
pumped). Individuals who are of reproductive potential must have agreed to use an
effective contraceptive method with details provided as a part of the consent
process. A person who has had menses at any time in the preceding 12 consecutive
months or who has semen likely to contain sperm is considered to be of "reproductive
potential." In addition to routine contraceptive methods, "effective contraception"
also includes refraining from sexual activity that might result in pregnancy and
surgery intended to prevent pregnancy (or with a side-effect of pregnancy
prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal
ligation/occlusion, and vasectomy with testing showing no sperm in the semen
- Participants must agree to have blood specimens submitted for circulating tumor DNA
(ctDNA)
- Participants must be offered participation in specimen banking. With participant
consent, specimens must be collected and submitted via the SWOG specimen tracking
system
- NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system
- Participants must be informed of the investigational nature of this study and
must sign and give informed consent in accordance with institutional and
federal guidelines. NOTE: Participants with impaired decision-making
capabilities, legally authorized representatives may sign and give informed
consent on behalf of study participants in accordance with applicable federal,
local, and Central Institutional Review Board (CIRB) regulations
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm I (ramucirumab, docetaxel) |
Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1 and docetaxel IV over 60 minutes on day 1 of each cycle (each cycle is 21 days). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study. |
|
|
Experimental Arm II (cemiplimab, ramucirumab, docetaxel) |
Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1, docetaxel IV over 60 minutes on day 1, and cemiplimab IV over 30 minutes on day 1 of each cycle (each cycle is 21 days). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study. |
|
Recruiting Locations
Daphne 4058219, Alabama 4829764 36526
Fairhope 4061234, Alabama 4829764 36532
Site Public Contact
251-435-4584
Mobile 4076598, Alabama 4829764 36607
Site Public Contact
251-435-3942
Saraland 4088628, Alabama 4829764 36571
Anchorage 5879400, Alaska 5879092 99508
Tucson 5318313, Arizona 5551752 85719
Tucson 5318313, Arizona 5551752 85719
Jonesboro 4116834, Arkansas 4099753 72401
Anaheim 5323810, California 5332921 92806
Baldwin Park 5325866, California 5332921 91706
Bellflower 5327422, California 5332921 90706
Beverly Hills 5328041, California 5332921 90211
Chico 5336269, California 5332921 95926
Site Public Contact
530-332-4700
Duarte 5344147, California 5332921 91010
Fontana 5349755, California 5332921 92335
Fresno 5350937, California 5332921 93720
Site Public Contact
833-574-2273
Fresno 5350937, California 5332921 93720
Harbor City 5355325, California 5332921 90710
Irvine 5359777, California 5332921 92618
Site Public Contact
877-467-3411
Irvine 5359777, California 5332921 92618
La Jolla 5363943, California 5332921 92093
Lancaster 5364940, California 5332921 93534
Loma Linda 5367696, California 5332921 92354
Site Public Contact
909-558-4050
Los Angeles 5368361, California 5332921 90027
Los Angeles 5368361, California 5332921 90034
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Marysville 5370984, California 5332921 95901
Site Public Contact
530-749-4400
Mather 5371065, California 5332921 95655
Oakland 5378538, California 5332921 94611
Ontario 5379439, California 5332921 91761
Palo Alto 5380748, California 5332921 94304
Site Public Contact
800-455-0057
Panorama City 5380932, California 5332921 91402
Rancho Mirage 5386015, California 5332921 92270
Site Public Contact
760-834-3798
Riverside 5387877, California 5332921 92505
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
San Diego 5391811, California 5332921 92120
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Marcos 5392368, California 5332921 92078
San Mateo 5392423, California 5332921 94401
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
South San Francisco 5397765, California 5332921 94080
Tarzana 5401143, California 5332921 91356
Site Public Contact
818-981-3818
Torrance 5403022, California 5332921 90505
Truckee 5403676, California 5332921 96161
Site Public Contact
530-582-6450
Upland 5404915, California 5332921 91786
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Woodland Hills 5410438, California 5332921 91367
Derby 4832745, Connecticut 4831725 06418
Fairfield 4834157, Connecticut 4831725 06824
Greenwich 4835395, Connecticut 4831725 06830
Guilford 4835512, Connecticut 4831725 06437
New Haven 4839366, Connecticut 4831725 06520
North Haven 4839704, Connecticut 4831725 06473
Stamford 4843564, Connecticut 4831725 06902
Torrington 4844309, Connecticut 4831725 06790
Trumbull 4844459, Connecticut 4831725 06611
Waterbury 4845193, Connecticut 4831725 06708
Waterford 8480031, Connecticut 4831725 06385
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20002
Gainesville 4156404, Florida 4155751 32610
Tampa 4174757, Florida 4155751 33612
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Atlanta 4180439, Georgia 4197000 30342
Duluth 4192289, Georgia 4197000 30096
Johns Creek 6331909, Georgia 4197000 30097
Lawrenceville 4205196, Georgia 4197000 30046
Savannah 4221552, Georgia 4197000 31405
Boise 5586437, Idaho 5596512 83712
Coeur d'Alene 5589173, Idaho 5596512 83814
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
DeKalb 4889553, Illinois 4896861 60115
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Geneva 4893591, Illinois 4896861 60134
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
312-695-1102
Grayslake 4894465, Illinois 4896861 60030
Site Public Contact
312-695-1102
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Kewanee 4898433, Illinois 4896861 61443
Lake Forest 4899012, Illinois 4896861 60045
Libertyville 4899739, Illinois 4896861 60048
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Oak Brook 4904277, Illinois 4896861 60523
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Oak Lawn 4904365, Illinois 4896861 60453
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Palos Heights 4905259, Illinois 4896861 60463
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Warrenville 4915525, Illinois 4896861 60555
Washington 4915545, Illinois 4896861 61571
Fairway 4271358, Kansas 4273857 66205
Hays 4272782, Kansas 4273857 67601
Site Public Contact
785-623-5774
Kansas City 4273837, Kansas 4273857 66160
Lawrence 4274277, Kansas 4273857 66044
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Lexington 4297983, Kentucky 6254925 40536
Site Public Contact
859-257-3379
Augusta 4957003, Maine 4971068 04330
Site Public Contact
207-626-4855
Belfast 4957956, Maine 4971068 04915
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Brunswick 4959473, Maine 4971068 04011
Rockport 4976817, Maine 4971068 04856
Sanford 4977762, Maine 4971068 04073
Site Public Contact
207-459-1600
South Portland 4979244, Maine 4971068 04106
Baltimore 4347778, Maryland 4361885 21229
Site Public Contact
410-368-2910
Baltimore 4347778, Maryland 4361885 21244
Cumberland 4352681, Maryland 4361885 21502
Site Public Contact
240-964-1400
Gaithersburg 4355843, Maryland 4361885 20879
Largo 4360345, Maryland 4361885 20774
Lutherville 4361379, Maryland 4361885 21093
Burlington 4931737, Massachusetts 6254926 01805
Peabody 4946863, Massachusetts 6254926 01960
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Pontiac 5006166, Michigan 5001836 48341
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Coon Rapids 5022025, Minnesota 5037779 55433
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Minneapolis 5037649, Minnesota 5037779 55407
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Sandstone 5045908, Minnesota 5037779 55072
Virginia 5051468, Minnesota 5037779 55792
Woodbury 5053358, Minnesota 5037779 55125
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
Gulfport 4428667, Mississippi 4436296 39502
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Creve Coeur 4382837, Missouri 4398678 63141
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Kansas City 4393217, Missouri 4398678 64108
Site Public Contact
816-404-4375
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
Osage Beach 4402040, Missouri 4398678 65065
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63136
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59804
Concord 5084868, New Hampshire 5090174 03301
Site Public Contact
603-224-2556
Lebanon 5088597, New Hampshire 5090174 03756
Manchester 5089178, New Hampshire 5090174 03103
Site Public Contact
800-339-6484
Moorestown 4503106, New Jersey 5101760 08057
Voorhees Township 5105860, New Jersey 5101760 08043
Albuquerque 5454711, New Mexico 5481136 87106
East Hills 5115904, New York 5128638 11548
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
The Bronx 5110266, New York 5128638 10461
The Bronx 5110266, New York 5128638 10468
Webster 5143495, New York 5128638 14580
West Islip 5143866, New York 5128638 11795
Site Public Contact
516-326-7514
Durham 4464368, North Carolina 4482348 27705
Pinehurst 4485272, North Carolina 4482348 28374
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Canton 5149222, Ohio 5165418 44710
Sylvania 5173572, Ohio 5165418 43560
Lawton 4540737, Oklahoma 4544379 73505
Site Public Contact
877-231-4440
Oklahoma City 4544349, Oklahoma 4544379 73104
Oklahoma City 4544349, Oklahoma 4544379 73109
Newberg 5742726, Oregon 5744337 97132
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Portland 5746545, Oregon 5744337 97239
Salem 5750162, Oregon 5744337 97301
Site Public Contact
503-561-2618
Beaver 5179446, Pennsylvania 6254927 15009
Butler 5182534, Pennsylvania 6254927 16001
Chambersburg 4557109, Pennsylvania 6254927 17201
Site Public Contact
717-217-6020
Cranberry Township 8643098, Pennsylvania 6254927 16066
Ephrata 5188815, Pennsylvania 6254927 17522
Site Public Contact
717-721-4840
Erie 5188843, Pennsylvania 6254927 16505
Farrell 5189377, Pennsylvania 6254927 16121
Gettysburg 4558183, Pennsylvania 6254927 17325
Site Public Contact
877-441-7957
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Indiana 5194868, Pennsylvania 6254927 15701
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
Lebanon 5197517, Pennsylvania 6254927 17042
McKeesport 5200499, Pennsylvania 6254927 15132
Site Public Contact
412-647-8073
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Monroeville 5201734, Pennsylvania 6254927 15146
Moon Township 5201821, Pennsylvania 6254927 15108
Mount Pleasant 5202281, Pennsylvania 6254927 15666
N. Huntingdon, Pennsylvania 6254927 15642
Natrona Heights 5202903, Pennsylvania 6254927 15065
Site Public Contact
724-230-3030
New Castle 5203127, Pennsylvania 6254927 16105
Philadelphia 4560349, Pennsylvania 6254927 19111
Site Public Contact
215-728-4790
Philadelphia 4560349, Pennsylvania 6254927 19140
Site Public Contact
215-728-2983
Pittsburgh 5206379, Pennsylvania 6254927 15215
Site Public Contact
412-784-4900
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
Seneca 5211432, Pennsylvania 6254927 16346
Site Public Contact
814-676-7900
Washington 5218069, Pennsylvania 6254927 15301
Williamsport 5219585, Pennsylvania 6254927 17701
Site Public Contact
800-598-4282
Williamsport 5219585, Pennsylvania 6254927 17754
York 4562407, Pennsylvania 6254927 17403
Site Public Contact
717-741-9229
Anderson 4569298, South Carolina 4597040 29621
Bluffton 4571722, South Carolina 4597040 29910
Hilton Head Island 4581832, South Carolina 4597040 29926-3827
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Amarillo 5516233, Texas 4736286 79106
Salt Lake City 5780993, Utah 5549030 84112
Saint Johnsbury 5240656, Vermont 5242283 05819
White River Junction 5242889, Vermont 5242283 05009
Site Public Contact
866-687-8387
Charlottesville 4752031, Virginia 6254928 22908
Lynchburg 4771075, Virginia 6254928 24501
McLean 4772354, Virginia 6254928 22102
Richmond 4781708, Virginia 6254928 23229
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
Woodbridge 4794457, Virginia 6254928 22192
Bridgeport 4800081, West Virginia 4826850 26330
Huntington 4809537, West Virginia 4826850 25701
Martinsburg 4813878, West Virginia 4826850 25401
Morgantown 4815352, West Virginia 4826850 26506
Parkersburg 4817641, West Virginia 4826850 26101
Ashland 5244247, Wisconsin 5279468 54806
Burlington 5247214, Wisconsin 5279468 53105
Cudahy 5249871, Wisconsin 5279468 53110
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54303
Green Bay 5254962, Wisconsin 5279468 54311
Kenosha 5258393, Wisconsin 5279468 53142
La Crosse 5258957, Wisconsin 5279468 54601
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marinette 5261852, Wisconsin 5279468 54143
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53233
Oconto Falls 5265522, Wisconsin 5279468 54154
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Summit, Wisconsin 5279468 53066
Two Rivers 5276609, Wisconsin 5279468 54241
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
More Details
- Status
- Recruiting
- Sponsor
- SWOG Cancer Research Network
Detailed Description
PRIMARY OBJECTIVE: I. To compare overall survival (OS) between participants randomized to docetaxel and ramucirumab with or without cemiplimab (REGN2810) who have acquired resistance to platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVES: I. To compare investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the arms. II. To compare investigator-assessed response rates (confirmed or unconfirmed, complete response [CR] or partial response [PR]) per RECIST 1.1 between the arms among participants with measurable disease. III. To compare the investigator-assessed disease control rate (confirmed or unconfirmed, complete response [CR], or partial response [PR], and stable disease) between the arms. IV. To evaluate the duration of response (DoR) among responders within each arm. V. To evaluate the frequency and severity of toxicities within each arm. VI. To compare investigator-assessed PFS between the arms within the subgroups defined by the stratification factors (histology and performance status) and by PD-L1 subgroups defined as PD-L1 negative (< 1% tumor proportion score [TPS]), intermediate PD-L1 (1-49% TPS), and PD-L1 high (>= 50% TPS). VII. To compare OS between the arms within the subgroups defined by the stratification factors (histology and performance status) and by PD-L1 subgroups defined as PD-L1 negative (< 1% TPS), intermediate PD-L1 (1-49% TPS), and PD-L1 high (>= 50% TPS). TRANSLATIONAL MEDICINE OBJECTIVES: I. To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) at baseline, cycle 3 day 1, and progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor DNA (ctDNA). II. To establish a tissue/blood repository to pursue future studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive dexamethasone orally (PO) twice daily (BID) on days 0-2, ramucirumab intravenously (IV) over 30-60 minutes on day 1 and docetaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study. ARM II: Patients receive dexamethasone PO BID on days 0-2, ramucirumab IV over 30-60 minutes on day 1, docetaxel IV over 60 minutes on day 1, and cemiplimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, and CT or MRI throughout the study. After completion of study treatment, patients are followed up every 3-6 months for up to 3 years after randomization.